Maxim Group Maintains Lipella Pharmaceuticals(LIPO.US) With Buy Rating, Maintains Target Price $2
Buy Rating Affirmed for Lipella Pharmaceuticals on LP-310's Phase 2a Enrollment and Strategic Advantages
Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Lipella Pharmaceuticals, Inc. (LIPO)
Lipella Pharmaceuticals Analyst Ratings
No Data